NCT/Study#

NCT04002401 /

KT-US-471-0114

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14)

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14)

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: